Market Cap 8.43M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 99,200
Avg Vol 694,060
Day's Range N/A - N/A
Shares Out 4.56M
Stochastic %K 45%
Beta 1.48
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: (954) 330-0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
invinc1ble
invinc1ble Oct. 25 at 3:26 PM
$SBFM market cap can double that point
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Oct. 24 at 11:53 PM
$SBFM very undervalued this company makes good revenue every year.!
0 · Reply
EZ_Money11
EZ_Money11 Oct. 24 at 9:47 PM
$SBFM I like the discount prices! 🏦
0 · Reply
Nuisance
Nuisance Oct. 24 at 4:08 PM
$SBFM come on...Back to three ☝️
1 · Reply
LH1965
LH1965 Oct. 24 at 2:42 PM
$SBFM Great to see that SBFM are reviving their share incentive plan. Not only will they need this for employee retention but it’s also a sign that management expect the SP to rise (nothing worse for morale than awarding senior exes with tanking share options). Perhaps more importantly, it will also give management significant pause for thought before doing anything rash that may inhibit SP growth (I.e. because employees being pissed off, and potentially walking, is an immediate threat to the company in a way that upset retail investors are not)
0 · Reply
MB66
MB66 Oct. 24 at 12:49 PM
$SBFM people who don’t understand why Longs here have little to No faith in the current management, good example: Sunshine Biopharma’s latest DEF 14A reveals severe shareholder control imbalance and major dilution risk. CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares, each with 1,000 votes, giving him over 96% of total voting power—leaving common shareholders with virtually no say in company decisions. The board is also asking “investors to approve” a massive increase in its 2023 Equity Incentive Plan, from just 1,661 shares to 683,000, a move that could dilute existing shareholders by more than 13%. Combined with repeated auditor changes, insider-friendly preferred stock issuances, and no separation between CEO and Chair, this filing underscores a deep governance imbalance and high risk for minority shareholders. Why hit us with an increase like this when they should be focusing on such programs after becoming profitable, not further dilution on shareholders backs.
2 · Reply
Planetpaprika
Planetpaprika Oct. 24 at 10:54 AM
$SBFM DEC 11 = shareholder meeting... https://www.sec.gov/Archives/edgar/data/1402328/000168316825007747/sunshine_def14a.htm
0 · Reply
Masterrunner
Masterrunner Oct. 24 at 1:53 AM
$SBFM The set up is perfect - the letdown is going to legendary!
1 · Reply
stockanalyzer777
stockanalyzer777 Oct. 23 at 9:32 PM
$SBFM Yes! A price escalation in share price is coming. Hold for gold and be patient. We willl soon be rewarded enormously.
0 · Reply
contra7
contra7 Oct. 23 at 8:44 PM
$SBFM News from the last 2 weeks here with the best ER in company history less than 2 weeks away.
0 · Reply
Latest News on SBFM
Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 11 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug


Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split


Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City


Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Announces Share Repurchase Program


Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma's Annual Letter to Shareholders


4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 3 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG


invinc1ble
invinc1ble Oct. 25 at 3:26 PM
$SBFM market cap can double that point
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Oct. 24 at 11:53 PM
$SBFM very undervalued this company makes good revenue every year.!
0 · Reply
EZ_Money11
EZ_Money11 Oct. 24 at 9:47 PM
$SBFM I like the discount prices! 🏦
0 · Reply
Nuisance
Nuisance Oct. 24 at 4:08 PM
$SBFM come on...Back to three ☝️
1 · Reply
LH1965
LH1965 Oct. 24 at 2:42 PM
$SBFM Great to see that SBFM are reviving their share incentive plan. Not only will they need this for employee retention but it’s also a sign that management expect the SP to rise (nothing worse for morale than awarding senior exes with tanking share options). Perhaps more importantly, it will also give management significant pause for thought before doing anything rash that may inhibit SP growth (I.e. because employees being pissed off, and potentially walking, is an immediate threat to the company in a way that upset retail investors are not)
0 · Reply
MB66
MB66 Oct. 24 at 12:49 PM
$SBFM people who don’t understand why Longs here have little to No faith in the current management, good example: Sunshine Biopharma’s latest DEF 14A reveals severe shareholder control imbalance and major dilution risk. CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares, each with 1,000 votes, giving him over 96% of total voting power—leaving common shareholders with virtually no say in company decisions. The board is also asking “investors to approve” a massive increase in its 2023 Equity Incentive Plan, from just 1,661 shares to 683,000, a move that could dilute existing shareholders by more than 13%. Combined with repeated auditor changes, insider-friendly preferred stock issuances, and no separation between CEO and Chair, this filing underscores a deep governance imbalance and high risk for minority shareholders. Why hit us with an increase like this when they should be focusing on such programs after becoming profitable, not further dilution on shareholders backs.
2 · Reply
Planetpaprika
Planetpaprika Oct. 24 at 10:54 AM
$SBFM DEC 11 = shareholder meeting... https://www.sec.gov/Archives/edgar/data/1402328/000168316825007747/sunshine_def14a.htm
0 · Reply
Masterrunner
Masterrunner Oct. 24 at 1:53 AM
$SBFM The set up is perfect - the letdown is going to legendary!
1 · Reply
stockanalyzer777
stockanalyzer777 Oct. 23 at 9:32 PM
$SBFM Yes! A price escalation in share price is coming. Hold for gold and be patient. We willl soon be rewarded enormously.
0 · Reply
contra7
contra7 Oct. 23 at 8:44 PM
$SBFM News from the last 2 weeks here with the best ER in company history less than 2 weeks away.
0 · Reply
RonRon1234
RonRon1234 Oct. 23 at 8:42 PM
$SBFM did they plan to sell their generic drugs in America? Do they have a time frame if so?
1 · Reply
Jdneri1
Jdneri1 Oct. 23 at 7:51 PM
$SBFM Don't give up, I sold over 26K shares of WKSP at $3.80 because I kew the CEO was pumping the stock and I found SBFM and realize it won't take too long to pay off.
0 · Reply
BmobyB
BmobyB Oct. 23 at 7:49 PM
$SBFM Good entry point prior to earnings IMO.
0 · Reply
LH1975New
LH1975New Oct. 23 at 1:28 PM
$SBFM In 2022, the company raised a whopping $35.5 million from the market. In 2025 (so far) the company has rasied $2.5 million from the market. Can you spot the difference?
1 · Reply
LH1975New
LH1975New Oct. 23 at 1:19 PM
$SBFM A reminder of the tremendous revenue growth since 2020: 2020: 71.41K 2021: 228.43K 2022: 4.35M 2023: 24.09M 2024: 34.87M 2025 (projected): 36-40M Go SBFM!
0 · Reply
Masterrunner
Masterrunner Oct. 23 at 12:57 PM
$SBFM Another beautiful & sunny day here; welcome to the 1.70s. Have a great day savvy investors!
3 · Reply
LH1975New
LH1975New Oct. 23 at 8:41 AM
0 · Reply
stockanalyzer777
stockanalyzer777 Oct. 22 at 9:17 PM
$SBFM Respectfully, why so bitter? Every company will have hiccups along the way during their starting phase. SBFM passed that stage and now on their way to a positive trajectory. The pharmaceutical industry is a multibillion dollar industry. I know this, because I order 90 percent of these medications with the exception of oncology medications . What I like about SBFM is that they provide generic drugs which are cheaper and are covered by 99% insurances. Positive news: Dont have to worry about tariffs Last earnings were positive Next earnings is scheduled for 11/2 They have multiple common generic drugs in their pipeline. The one likely to bring more revenue is the niopeg. The stock price is 1.83---target price is $7.00 at minimum. HUGE POTENTIAL FOR UPSIDE.
2 · Reply
Masterrunner
Masterrunner Oct. 22 at 8:33 PM
$SBFM Today's analysis - It's coiling and is ready to explode (in your face 😂)! Like I mentioned last week, it's going to be all downhill since last week's Warrant pump & dump scheme to the next pump & dump scheme sometime in 2026
1 · Reply
contra7
contra7 Oct. 22 at 8:24 PM
$SBFM Today’s tape analysis 🧐 More manipulation to provoke FUD (Fear Uncertainty Doubt) before the next leg up
0 · Reply
Nova_Pup_
Nova_Pup_ Oct. 22 at 6:41 PM
$SBFM New here. Targets: ☑️$3.50 ☑️$4.18 ☑️$26.79 ☑️$117.62 ☑️$682.48 ☑️$2,439,625.02 - would be wild lol but that’s what the data says, most likely thrown off by the stock splits There are the targets, I’ll update when we hit. Let’s see what happens!
1 · Reply
Masterrunner
Masterrunner Oct. 22 at 6:08 PM
$SBFM Wow! Get those cheapies ''while it lasts'' or even better invest in a real Biotech - your choice!
0 · Reply